Antiviral therapy with either ganciclovir or valganciclovir has shown moderate benefit in
prevention of hearing deterioration among infants with clinically apparent CMV infection or …

More research is needed to determine the region-specific applicability of the new European
recommendations for routine CMV screening in pregnancy. Areas of uncertainty in postnatal …

Congenital cytomegalovirus (cCMV) continues to be a major public health care issue due to
its high prevalence throughout the world. However, there is a paucity of studies evaluating …

Objective To assess the efficacy of valganciclovir in infants with hearing loss and clinically
inapparent congenital cytomegalovirus infection (cCMV), as there is no consensus on …

Congenital cytomegalovirus (cCMV) infection is the leading nongenetic cause of
sensorineural hearing loss (SNHL) in children. 1 In the United States, cCMV occurs in an …

Among 342 US infants with congenital cytomegalovirus treated with antivirals, 114 (33%)
received ganciclovir (with or without valganciclovir) and 228 (67%) received valganciclovir …

Background: Congenital cytomegalovirus (cCMV) infection is the leading cause of non-
hereditary sensorineural hearing loss in children. While about 10% of children reportedly …

Purpose: The purpose of this study was to inform the revision of a targeted surveillance risk
registry by identifying which risk factors predict postnatally identified hearing loss (PNIHL) in …

Background: Human cytomegalovirus (hCMV) is the most common etiological agent of
congenital infections seen in newborns. Among the most commonly observed complications …

Congenital cytomegalovirus (cCMV) infection is the most common congenital infection in
developed countries. Although a standard therapy has not yet been established, evidence …